TREML6 Inhibitors
TREML6 inhibitors belong to a class of compounds designed to modulate the activity of the Triggering Receptor Expressed on Myeloid Cells-Like 6 (TREML6), a member of the TREM receptor family. TREML6 is a type I transmembrane glycoprotein predominantly expressed in various myeloid cell populations. It plays a significant role in regulating immune responses and inflammation by interacting with ligands involved in the immune signaling pathways. By inhibiting TREML6, these compounds alter the receptor's ability to modulate signaling cascades, thus affecting downstream processes in myeloid cells such as the activation of transcription factors, cytokine production, and cell surface molecule expression. The design of TREML6 inhibitors involves structural modifications aimed at targeting the extracellular domains of TREML6, either by interfering with its ligand-binding capacity or by altering its conformation, preventing its proper function.
Chemically, TREML6 inhibitors are typically composed of small molecules or biologics that interact specifically with the receptor's binding sites. The inhibitors are structurally optimized to have high selectivity for TREML6 over other members of the TREM receptor family to reduce off-target effects and unintended interactions with related proteins. In the development and study of TREML6 inhibitors, computational modeling techniques are often used to predict the binding affinities of these inhibitors to TREML6. Techniques like X-ray crystallography and NMR spectroscopy are employed to determine the inhibitor-receptor interaction at a molecular level, enabling further optimization of inhibitor structures. These compounds are valuable tools in molecular biology research, as they provide insights into the role of TREML6 in immune signaling and its broader implications in immune system regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A769662 may inhibit TREML6 expression by potentially acting as an AMP-activated protein kinase (AMPK) activator. Activation of AMPK could lead to downstream effects on cell signaling pathways that may interfere with the expression of TREML6, as AMPK has been linked to the regulation of immune responses and inflammatory processes, potentially impacting TREML6 expression. | ||||||
BAY-876 | 1799753-84-6 | sc-507539 | 5 mg | $240.00 | ||
BAY-876 may inhibit TREML6 expression by potentially acting as a selective inhibitor of phosphoinositide 3-kinase (PI3K). Inhibition of PI3K activity could lead to downstream effects on cell signaling pathways that may interfere with the expression of TREML6, as PI3K has been implicated in the regulation of immune responses and inflammatory processes, potentially impacting TREML6 expression. | ||||||
TW-37 | 877877-35-5 | sc-361387 sc-361387A | 10 mg 50 mg | $200.00 $860.00 | 2 | |
CAY10505 may inhibit TREML6 expression by potentially acting as an inhibitor of nuclear factor kappa B (NF-κB) activation. Inhibition of NF-κB activation could lead to downstream effects on cell signaling pathways that may interfere with the expression of TREML6, as NF-κB has been implicated in the regulation of immune responses and inflammatory processes, potentially impacting TREML6 expression. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsomorphin may inhibit TREML6 expression by potentially acting as an inhibitor of AMP-activated protein kinase (AMPK). Inhibition of AMPK activity could lead to downstream effects on cell signaling pathways that may interfere with the expression of TREML6, as AMPK has been linked to the regulation of immune responses and inflammatory processes, potentially impacting TREML6 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 may inhibit TREML6 expression by potentially acting as a selective inhibitor of phosphoinositide 3-kinase (PI3K). Inhibition of PI3K activity could lead to downstream effects on cell signaling pathways that may interfere with the expression of TREML6, as PI3K has been implicated in the regulation of immune responses and inflammatory processes, potentially impacting TREML6 expression. | ||||||
PF-543 | 1415562-82-1 | sc-507507 | 10 mg | $210.00 | ||
PF-543 may inhibit TREML6 expression by potentially acting as a selective inhibitor of sphingosine kinase 1 (SphK1). Inhibition of SphK1 activity could lead to downstream effects on cell signaling pathways that may interfere with the expression of TREML6, as SphK1 has been linked to the regulation of immune responses and inflammatory processes, potentially impacting TREML6 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 may inhibit TREML6 expression by potentially acting as an inhibitor of p38 mitogen-activated protein kinases (MAPK). Inhibition of p38 MAPK could lead to downstream effects on cell signaling pathways that may interfere with the expression of TREML6, as p38 MAPK has been linked to the regulation of immune responses and inflammatory processes, potentially impacting TREML6 expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 may inhibit TREML6 expression by potentially acting as an inhibitor of c-Jun N-terminal kinases (JNK). Inhibition of JNK activity could lead to downstream effects on cell signaling pathways that may interfere with the expression of TREML6, as JNK has been linked to the regulation of immune responses and inflammatory processes, potentially impacting TREML6 expression. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 may inhibit TREML6 expression by potentially acting as a dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). Inhibition of PI3K and mTOR activities could lead to downstream effects on cell signaling pathways that may interfere with the expression of TREML6, as PI3K and mTOR have been implicated in the regulation of immune responses and inflammatory processes, potentially impacting TREML6 expression. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
BIRB 796 may inhibit TREML6 expression by potentially acting as an inhibitor of p38 mitogen-activated protein kinases (MAPK). Inhibition of p38 MAPK could lead to downstream effects on cell signaling pathways that may interfere with the expression of TREML6, as p38 MAPK has been linked to the regulation of immune responses and inflammatory processes, potentially impacting TREML6 expression. | ||||||